Pharmaceutical Technology

JUNE 24, 2022

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.

Biopharma 64

Biopharma Pharma Pharmacology Healthcare 64

pharmaphorum

AUGUST 11, 2022

The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.

Pharmacology 59

Pharmacology Biopharma Pharma 59

pharmaphorum

DECEMBER 20, 2022

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. Although, so far efforts to bring a therapy to market have failed.

Pharmacology 52

Pharmacology Marketing Pharma Biopharma 52

Clarivate

FEBRUARY 28, 2023

Frontiers in Pharmacology; 13:1089033; DOI: 10.3389/fphar.2022.1089033 .” Ophthalmology; V.127; 5; 5/2020; p679; DOI: 10.1016/j.ophtha.2019.11.014 2019.11.014 [8] Giannuzzi V et al. Editorial: The Use of Real World Data for Regulatory Purposes in the Rare Diseases Setting.”

Patients 98

Patients Prescription Pharmacology Healthcare 98

MedCity News

JUNE 16, 2023

Numerous clinical, regulatory and financial factors are behind this digital shift in pharma. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development.

Pharma 311

Pharma Food and Drug Administration Recruitment Patients 311

European Pharmaceutical Review

OCTOBER 27, 2022

Ahead of the world’s largest pharma event, CPHI Frankfurt – hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics outsourcing and contract manufacturing organisastions (CMOs) in 2023. percent in 2022.

Biopharma 98

Biopharma Manufacturing Pharmacology Marketing 98

Clarivate

DECEMBER 14, 2023

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111

Pharma Government Pharmacology Healthcare 111